Yigenoglu, Tugce NurBasci, SemihSahin, DeryaUlas, TurgayDal, Mehmet SinanKorkmaz, SerdalHacibekiroglu, Tuba2024-08-042024-08-0420211473-05021878-1683https://doi.org/10.1016/j.transci.2021.103237https://hdl.handle.net/11616/100172SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARSCoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.eninfo:eu-repo/semantics/openAccessMesenchymal stem cellCOVID-19SARS-CoV-2TransfusionTransplantationReview Article6063441935610.1016/j.transci.2021.1032372-s2.0-85113813802Q3WOS:000733239700018Q4